Selank
Limited human dataAlso known as: TP-7 · Tuftsin-analogue heptapeptide
A synthetic heptapeptide anxiolytic developed alongside Semax at Russia's Institute of Molecular Genetics, studied for generalized anxiety disorder and neurasthenia. Frequently paired with Semax in nootropic-peptide discussions.
Mechanism (plain language)
An analogue of the immunomodulatory peptide tuftsin, proposed to act on GABAergic signaling and enkephalin metabolism rather than through benzodiazepine receptor binding, which is the basis for claims of anxiolytic effects "without" classic sedative-hypnotic side effects.
What research suggests
Randomized comparative trials in patients with generalized anxiety disorder and neurasthenia report anxiolytic effects comparable to benzodiazepines like medazepam and phenazepam, plus modest nootropic and immunomodulatory effects, without the sedation or dependence typically seen with benzodiazepines.
Uncertainties & risks
Nearly all human data comes from Russian trials with relatively small samples; independent, large-scale, international replication is lacking. Long-term safety data outside these trials is limited, and mechanism claims (GABAergic modulation, enkephalin effects) are not fully settled.
STACKD study summaries
Start with our in-house roundups—plain-language synthesis of the research, with primary sources cited at the bottom of each.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.
- Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia
2008 · human
Randomized comparison with medazepam found similar anxiolytic effect plus antiasthenic/psychostimulant effects.
- A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in the treatment of anxiety disorders
2014 · human
Selank showed anxiolytic and mild nootropic effects lasting up to a week after the last dose in a comparative trial.